Clinical aspects of plasma platelet-activating factor-acetylhydrolase

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1761, Issue 11, 2006, Pages 1359-1372

  Karasawa, Ken ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

Asthma; Atherogenesis; Atherosclerosis; Inflammation; Lipoprotein; Oxidized phospholipid; PAF; PAF AH; Platelet activating factor; Platelet activating factor acetylhydrolase; Shock

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; ESTERASE INHIBITOR; FATTY ACID; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; LEVOTHYROXINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; PHOSPHOLIPID; RECOMBINANT 1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; RECOMBINANT ENZYME; SB 22657; SB 480848; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ADENOVIRUS VECTOR; ANAPHYLACTIC SHOCK; ASTHMA; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL TRIAL; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME POLYMORPHISM; ENZYME SUBSTRATE; ENZYME SYNTHESIS; GENE TRANSFER; HUMAN; HYPOTHYROIDISM; INFLAMMATORY DISEASE; LIPID OXIDATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SEPSIS; SEPTIC SHOCK; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; ASTHMA; ATHEROSCLEROSIS; FATTY ACIDS; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LYSOPHOSPHATIDYLCHOLINES; OXIDATION-REDUCTION; RECOMBINANT PROTEINS; SHOCK, SEPTIC;

EID: 33750943178     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2006.06.017     Document Type: Review

References (163)

1. Prescott S.M., Zimmerman G.A., Stafforini D.M., and McIntyre T.M. Platelet-activating factor and related lipid mediators. Annu. Rev. Biochem. 69 (2000) 419-445
2. Honda Z., Nakamura M., Miki I., Minami M., Watanabe T., Seyama Y., Okado H., Toh H., Ito K., Miyamoto T., and Shimizu T. Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature 349 (1991) 342-346
3. 2 enzymes: classification and characterization. Biochem. Biophys. Acta 1488 (2000) 1-19
4. Arai H. Platelet-activating factor acetylhydrolase. Prostaglandins Other Lipid Mediat. 68-69 (2002) 83-94
5. Blank M.L., Lee T., Fitzgerald V., and Snyder F. A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J. Biol. Chem. 256 (1981) 175-178
6. Moon T.C., Kim M.S., Lee S.J., Lee T.Y., Kwon S.H., Baek S.H., and Chang H.W. Detection and characterization of 45 kDa platelet activating factor acetylhydrolase in cerebrospinal fluid of children with meningitis. Arch. Pharm. Res. 26 (2003) 554-558
7. Tjoelker L.W., Wilder C., Eberhardt C., Stafforini D.M., Dietsch G., Schimpf B., Hooper S., Le Trong H., Cousens L.S., Zimmerman G.A., Yamada Y., McIntyre T.M., Prescott S.M., and Gray P.W. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374 (1995) 549-553
8. 2 with a catalytic triad. J. Biol. Chem. 270 (1995) 25481-25487
9. Asano K., Okamoto S., Fukunaga K., Shiomi T., Mori T., Iwata M., Ikeda Y., and Yamaguchi K. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem. Biophys. Res. Commun. 261 (1999) 511-514
10. Stafforini D.M., Elstad M.R., McIntyre T.M., Zimmerman G.A., and Prescott S.M. Human macrophages secrete platelet-activating factor acetylhydrolase. J. Biol. Chem. 265 (1990) 9682-9687
11. Stafforini D.M., Tjoelker L.W., McCormick S.P., Vaitkus D., McIntyre T.M., Gray P.W., Young S.G., and Prescott S.M. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J. Biol. Chem. 274 (1999) 7018-7024
12. Tselepis A.D., Dentan C., Karabina S.A., Chapman M.J., and Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1764-1773
13. Chapman M.J., Guerin M., and Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur. Heart J. 19 (1998) A24-A30
14. 2 and small, dense low-density lipoprotein. Curr. Opin. Lipidol. 11 (2000) 465-471
15. 2+-induced oxidative modification in vitro. Atherosclerosis 125 (1996) 121-134
16. Benitez S., Sanchez-Quesada J.L., Ribas V., Jorba O., Blanco-Vaca F., Gonzalez-Sastre F., and Ordonez-Lianos J. Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation 108 (2003) 92-96
17. Savanian A., Hwang J., Hodis H., Cazzolato G., Avogaro P., and Bittolo-Bon G. Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subfractions. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 784-793
18. De Castelanau S., Sanchez-Quesada J.L., Benitrez S., Rosa R., Caveda L., Vila L., and Ordonez-Llanos J. Electronegative LDL from normolipidemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2281-2287
19. Sanchez-Quesada J.L., Camacho M., Anton R., Benitez S., Vila L., and Ordonez-Llanos J. Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis 166 (2003) 261-270
20. Hodis H.N., Kramsch D.M., Avogaro P., Bittolo-Bon G., Cazzolato G., Hwang J., Peterson H., and Sevanian A. Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low-density lipoprotein (electronegative LDL). J. Lipid Res. 35 (1994) 669-677
21. Demuth K., Myara I., Chappey B., Vedie B., Pech-Amsellem M.A., Haberland M.F., and Moatti N. A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 773-783
22. Sugatani J., Miwa M., Komiyama Y., and Murakami T. Quantitative analysis of platelet-activating factor in human plasma. Application to patients with liver cirrhosis and disseminated intravascular coagulation. J. Immunol. Methods 166 (1993) 251-261
23. Stafforini D.M., Prescott S.M., and McIntyre T.M. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J. Biol. Chem. 262 (1987) 4223-4230
24. Tew D.G., Southan C., Rice S.Q., Lawrence M.P., Li H., Boyd H.F., Moores K., Gloger I.S., and Macphee C.H. Purification, properties sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 591-599
25. Graham R.M., Stephens C.J., Silvester W., Leong L.L., Sturm M.J., and Taylor R.R. Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Crit. Care Med. 22 (1994) 204-212
26. Liu M., and Subbaiah P.V. Hydrolysis and transesterification of platelet-activating factor by lecithin-cholesterol acyltransferase. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 6035-6039
27. Rodrigo L., Mackness B., Durrington P.N., Hernandez A., and Mackness M.I. Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem. J. 354 (2001) 1-7
28. Marathe G., Zimmerman G.A., and McIntyre T.M. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolysis of high density lipoprotein particles. J. Biol. Chem. 278 (2003) 3937-3947
29. Connelly P.W., Draganov D., and Maguire G.F. Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite. Free Radic. Biol. Med. 38 (2005) 164-174
30. Karasawa K., Harada A., Satoh N., Inoue K., and Setaka M. Plasma platelet activating factor-acetylhydrolase. Prog. Lipid Res. 42 (2003) 93-114
31. Stremler K.E., Stafforini D.M., Prescott S.M., and McIntyre T.M. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J. Biol. Chem. 266 (1991) 11095-11103
32. Min J.H., Wilder C., Aoki J., Inoue K., Paul L., and Gelb M.H. Platelet-activating factor acetylhydrolases: broad substrate specificity and lipoprotein binding does not modulate the catalytic properties of the plasma enzyme. Biochemistry 40 (2001) 4539-4549
33. Marathe G.K., Davies S.S., Harrison K.A., Silva A.R., Murphy R.C., Castro-Faria-Neto H., Prescott S.M., Zimmerman G.A., and McIntyre T.M. Inflammatory platelet-activating-factor like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. J. Biol. Chem. 274 (1999) 28395-28404
34. Watson A.D., Leitinger N., Navab M., Faull K.F., Horkko S., Witztum J.L., Palinski W., Schwenke D., Salomon R.G., Sha W., Subbanagounder G., Fogelman A.M., and Berliner J.A. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272 (1997) 13597-13607
35. Watson A.D., Leitinger N., Navab M., Faull K.F., Horkko S., Witztum J.L., Palinski W., Schwenke D., Salomon R.G., Sha W., Subbanagounder G., Fogelman A.M., and Berliner J.A. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272 (1997) 13597-13607
36. Leitinger N., Tyner T.R., Oslund L., Rizza C., Subbanagounder G., Lee H., Shih P.T., Mackman N., Tigyi G., Territo M.C., Berliner J.A., and Vora D.K. Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 12010-12015
37. Androulakis N., Durand H., Ninio E., and Tsoukatos D.C. Molecular and mechanistic characterization of platelet-activating factor-like bioactivity produced upon LDL oxidation. J. Lipid Res. 46 (2005) 1923-1932
38. 2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J. Biol. Chem. 281 (2006) 4616-4623
39. Fam S.S., and Morrow J.D. The isoprostanes: unique products of arachidonic acid oxidation-A review. Curr. Med. Chem. 10 (2003) 1723-1740
40. Morrow J.D. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 279-286
41. Witztum J.L., and Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88 (1991) 1785-1792
42. Collins T., and Cybulsky M.I. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?. J. Clin. Invest. 107 (2001) 255-264
43. Bobryshev Y.V. Dendritic cells and their involvement in atherosclerosis. Curr. Opin. 11 (2000) 511-517
44. Llodra J., Angeli V., Liu J., Trogan E., Fisher E.A., and Randolph G.J. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11779-11784
45. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem. J. 338 (1999) 479-487
46. Sakai M., Miyazaki A., Hakamata H., Kobori S., Shichiri M., and Horiuchi S. Endocytic uptake lf lysophosphatidylcholine mediated by macrophage scavenger receptor plays a major role in oxidized low density lipoprotein-induced macrophage growth. J. Atheroscler. Thromb. 2 (1996) 81-86
47. Kume N., Cybulsky M.I., and Gimbrone Jr. M.A. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 90 (1992) 1138-1144
48. 2 reaction leads to increased monocyte adhesion of endothelial cells via the expression of adhesion molecules. Eur. J. Biochem. 217 (1993) 723-729
49. Kugiyama K., Kerns S.A., Morrisett J.D., Roberts R., and Henry P.D. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344 (1990) 160-162
50. Liu S.Y., Lu X., Choy S., Dembinski T.C., Hatch G.M., Mymin D., Shen X., Angel A., Choy P.C., and Man R.Y. Alteration of lysophosphatidylcholine content in low density lipoprotein after oxidative modification: relationship to endothelium dependent relaxation. Cardiovasc. Res. 28 (1994) 1476-1481
51. Nakano T., Raines E.W., Abraham J.A., Klagsbrun M., and Ross R. Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 1069-1073
52. Kume N., and Gimbrone M.A. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J. Clin. Invest. 93 (1994) 907-911
53. Nishi E., Kume N., Ochi H., Moriwaki H., Wakatsuki Y., Higashiyama S., Taniguchi N., and Kita T. Lysophosphatidylcholine increases expression of heparin-binding epidermal growth factor-like growth factor in human T lymphocytes. Circ. Res. 80 (1997) 638-644
54. 2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Artherioscler. Thromb. Vasc. Biol. 19 (1999) 2909-2917
55. 2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 2257-2263
56. 2 with high specificity for oxidized phospholipids and platelet activating factor. Biochem. J. 330 (1998) 1309-1315
57. Tsimihodimos V., Karabina S.A., Tambaki A.P., Bairaktari E., Miltiadous G., Goudevenos J.A., Cariolou M.A., Chapman M.J., Tselepis A.D., and Elisaf M. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J. Lipid Res. 43 (2002) 256-263
58. Tsimihodimos V., Kakafika A., Tambaki A.P., Bairaktari E., Chapman M.J., Eisaf M., and Tselepis A.D. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J. Lipid Res. 44 (2003) 927-934
59. Tambaki A.P., Rizos E., Tsimihodimos V., Tselepis A.D., and Elisaf M. Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associate platelet activating factor-acetylhydrolase activity. J. Cardiovasc. Pharmacol. Ther. 9 (2004) 91-95
60. Navab M., Berliner J.A., Subbanagounder G., Hama S., Lusis A.J., Castellani L.W., Reddy S., Shih D., Shi W., Watson A.D., Van Lenten B.J., Vora D., and Fogelman A.M. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 481-488
61. Tsimihodimos V., Karabina S.-.A.P., Tambaki A.P., Bairakrari E., Goudevenos J.A., Chapman M.J., Elisaf M., and Tselepis A.D. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of Type IIA and IIB. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 306-311
62. Eisaf M., and Tselepis A.D. Effect of hypolipidemic drugs on lipoprotein-associated platelet-activating factor acetylhydrolase. Implication for atherosclerosis. Biochem. Pharmacol. 66 (2003) 2069-2073
63. Kujiraoka T., Iwasaki T., Ishihara M., Ito M., Nagano M., Kawaguchi A., Takahashi S., Ishii J., Tsuji M., Egashira T., Stepanova I.P., Miller N.E., and Hattori H. Altered distribution of plasma PAF-AH between HLDs and other lipoproteins in hyperlipidemia and diabetes mellitus. J. Lipid Res. 44 (2003) 2006-20014
64. Nanjee M.N., Doran J.E., Lerch P.G., and Miller N.E. Acute effects of intravenous infusion of Apo A-I/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 979-989
65. Kujiraoka T., Hattori H., Ito M., Nanjee N., Ishihara M., Nagano M., Iwasaki T., Cooke C.J., Olszewski W.L., Stepanova I.P., Egashira T., and Miller N.E. Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid. Atherosclerosis 176 (2004) 57-62
66. Castellani L.W., Navab M., Van Lenten B.J., Hedrick C.C., Hama S.Y., Goto A.M., Fogelman A.M., and Lusis A.J. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J. Clin. Invest. 100 (1997) 464-474
67. Ribas V., Sanchez-Quesada J.L., Anton R., Camacho M., Julve J., Escola-Gil J.C., Vila L., Ordonez-Llanos J., and Blanco-Vaca F. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ. Res. 95 (2004) 789-797
68. Boisfer E., Stengel D., Pastier D., Laplaud P.M., Dousset N., Ninio E., and Kalopissis A.D. Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II. J. Lipid Res. 43 (2002) 732-741
69. Angeli V., Liodra J., Rong J.X., Satoh K., Ishii S., Shimizu T., Fisher E.A., and Randolph G.J. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 21 (2004) 561-574
70. 2 platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150 (2000) 413-419
71. 2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 343 (2000) 1179-1182
72. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110 (2004) 1903-1908
73. 2 levels and the risk of future cardiovascular events in women. J. Am. Coll. Cardiol. 38 (2001) 1302-1306
74. Satoh K., Imaizumi T., Yoshida H., Kawamura Y., Takamatsu S., Takamatsu M., and Mizuno S. Platelet-activating factor acetylhydrolase in plasma lipoproteins of healthy men and women. Clin. Chim. Acta 202 (1991) 95-103
75. Kosaka T., Yamaguchi M., Miyanaga K., and Mizuno K. Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese. Clin. Chim. Acta 312 (2001) 179-183
76. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart diseases in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109 (2004) 837-842
77. Winkler K., Winkelmann B.R., Scharnagl H., Hofmann M.M., Grawitz A.B., Nauck M., Bohm B.O., and Marz W. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors. Circulation 111 (2005) 980-987
78. Blankenberg S., Stengel D., Rupprecht H.J., Bickel C., Meyer J., Cambien F., Tiret L., and Ninio E. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J. Lipid Res. 44 (2003) 1381-1386
79. Singh U., Zhong S., Xiong M., Li T.B., Sniderman A., and Teng B.B. Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice. Clin. Sci. 106 (2004) 421-432
80. 2 inhibition: a novel, non-lipid lowering strategy for atherosclerosis therapy. Farmaco 56 (2001) 45-50
81. 2 for evaluation in man. Bioorg. Med. Chem. Lett. 12 (2002) 2603-2606
82. 2 diminishes the death-inducing effects of oxidized LDL on human monocyte-macrophages. FEBS Lett. 505 (2001) 357-363
83. 2 for evaluation in man. Bioorg. Med. Chem. Lett. 12 (2002) 2603-2606
84. Rotella D.P. SB-480848. Curr. Opin. Investig. Drugs 5 (2004) 348-351
85. Wu X., Zimmerman G.A., Prescott S.M., and Stafforini D.M. The p38 MAPK pathway mediates transcriptional activation of the plasma platelet-activating factor acetylhydrolase gene in macrophages stimulated with lipopolysaccharide. J. Biol. Chem. 279 (2004) 36158-36165
86. Howard K.M., and Olson M.S. The expression and localization of plasma platelet-activating factor acetylhydrolase in endotoxemic rats. J. Biol. Chem. 275 (2000) 19891-19896
87. Miwa M., Miyake T., Yamanaka T., Sugatani J., Suzuki Y., Sakata S., Araki Y., and Matsumoto M. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J. Clin. Invest. 82 (1988) 1983-1991
88. Stafforini D.M., Satoh K., Atkinson D.L., Tjoelker L.W., Eberhardt C., Yoshida H., Imaizumi T., Takamatsu S., Zimmerman G.A., McIntyre T.M., Gray P.W., and Prescott S.M. Platelet activating factor acetylhydrolase deficiency. A missense mutation near the active site of anti-inflammatory phospholipase. J. Clin. Invest. 97 (1996) 2784-2791
89. Yamada Y., and Yokota M. Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281Arg mutation. Biochem. Biophys. Res. Commun. 236 (1997) 772-775
90. 2) deficiency patients. J. Hum. Genet. 49 (2004) 302-307
91. Yamada Y., Ichihara S., Fujimura T., and Yokota M. Identification of the G994 → T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 47 (1998) 177-181
92. Hiramoto M., Yoshida H., Imaizumi T., Yoshimizu N., and Satoh K. A mutation in plasma platelet-activating factor acetylhydrolase (Val279 → Phe) is a genetic risk factor for stroke. Stroke 28 (1997) 2417-2420
93. Ichihara S., Yamada Y., and Yokota M. Association of a G994 → T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with genetic susceptibility to nonfamilial dilated cardiomyopathy in Japanese. Circulation 98 (1998) 1881-1885
94. Yamada Y., Ichihara S., Izawa H., Tanaka M., and Yokota M. Association of a G994 → T (Val279 → Phe) polymorphism of the plasma platelet-activating factor acetylhydrolase gene with myocardial damage in Japanese patients with nonfamilial hypertrophic caridomyopathy. J. Hum. Genet. 46 (2001) 436-441
95. Yoshida H., Imaizumi T., Fujimoto K., Itaya H., Hiramoto M., Yoshimizu N., Fukushi K., and Satoh K. A mutation in plasma platelet activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension. Thromb. Haemost. 80 (1998) 372-375
96. Unno N., Nakamura T., Kaneko H., Uchiyama T., Yamamoto M., Sugatani J., Miwa M., and Nakamura S. Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in Japan. J. Vasc. Surg. 32 (2000) 263-267
97. Unnno N., Nakamura T., Mitsuoka H., Saito T., Miki K., Ishimaru K., Sugatani K., Miwa M., and Nakamura S. Single nucleotide polymorphism (G994 → T) in the plasma platelet-activating factor acetylhydrolase gene is associated with graft patency of femoropopliteal bypass. Surgery 132 (2002) 66-71
98. Shimokata K., Yamada Y., Kondo T., Ichihara S., Izawa H., Nagata K., Murohara T., Ohno M., and Yokota M. Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia. Atherosclerosis 172 (2004) 167-173
99. Balta G., Gurgey A., Kudayarov D.K., Tunc B., and Altay C. Evidence for the existence of the PAF acetylhydrolase mutation (Val279Phe) in non-Japanese populations: a preliminary study in Turkey, Azerbaijan, and Kyrgyzstan. Thormb. Res. 101 (2001) 231-234
100. 2 gene for polymorphic variants and case-control analysis in schizophrenia. Biochem. Biophys. Res. Commun. 241 (1997) 630-635
101. Ninio E., Tregouet D., Carrier J.L., Stengel D., Bickel C., Perret C., Rupprecht H.J., Cambien F., Blankenberg S., and Tiret L. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum. Mol. Genet. 13 (2004) 1341-1351
102. Campo S., Sardo M.A., Bitto A., Bonaiuto A., Trimarchi G., Banaiuto M., Castaldo M., Saitta C., Cristadoro S., and Saitta A. Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals. Clin. Chem. 50 (2004) 2077-2082
103. Theilmeier G., De Geest B., Van Veldhoven P.P., Stengel D., Michiels C., Lox M., Landeloos M., Chapman M.J., Ninio E., Collen D., Himpens B., and Holvoet P. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J. 14 (2000) 2032-2039
104. De Geest B., Stengel D., Landeloos M., Lox M., Le Gat L., Collen D., Holvoet P., and Ninio E. Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis. Arterioscler. Tromb. Vasc. Biol. 20 (2000) 68-75
105. Quarck R., De Geest B., Stengel D., Mertens A., Lox M., Theilmeier G., Michiels C., Raes M., Bult H., Collen D., Van Veldhoven P., Ninio E., and Holvoet P. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 103 (2001) 2495-2500
106. Noto H., Hara M., Karasawa K., Iso-O N., Satoh H., Togo M., Hashimoto Y., Yamada Y., Kosaka T., Kawamura M., Kimura S., and Tsukamoto K. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 829-835
107. Arakawa H., Qian J.Y., Baatar D., Karasawa K., Asada Y., Sasaguri Y., Miller E.R., Witztum J.L., and Ueno H. Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits. Circulation 111 (2005) 3302-3309
108. Rubin A.H., Smith L.J., and Patterson R. The bronchoconstrictor properties of platelet-activating factor in humans. Am. Rev. Respir. Dis. 136 (1987) 1145-1151
109. Henderson Jr. W.R. Eicosanoids and platelet-activating factor in allergic respiratory diseases. Am. Rev. Respir. Dis. 143 (1991) S86-S90
110. Diaz O., Barbera J.A., Marrades R., Chung K.F., Roca J., and Rodriguez-Roisin R. Inhibition of PAF-induced gas exchange defects by beta-adrenergic agonists in mild asthma is not due to bronchodilation. Am. J. Respir. Crit. Care Med. 156 (1997) 17-22
111. Guinot P., Brambilla C., Duchier J., Braquet P., Bonvoisin B., and Cournot A. Effect of BN52063, a specific PAF-acether antagonist, on bronchial provocation test to allergens in asthmatic patients. A preliminary study. Prostaglandins 34 (1987) 723-731
112. O'Connor B.J., Uden S., Carty T.J., Eskra J.D., Barns P.J., and Chung K.F. Inhibitory effect of UK74505 a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans. Am. J. Respir. Crit. Care Med. 150 (1994) 35-40
113. Hahn H.L., Purnama I., Lang M., and Sannwald U. Effects of platelet-activating factor on tracheal mucus secretion, on airway mechanics and on circulating blood cells in liver ferrets. Eur. J. Respir. Dis. 146 (1986) 277-284
114. Lang M., Hansen D., and Hahn H.L. Effects of the PAF-antagonist CV-3988 on PAF-induced changes in mucus secretion and in respiratory and circulatory variables in ferrets. Agents Actions 21 (1987) 245-252
115. Humphrey D.M., McManus L.M., Satouchi K., Hanahan D.J., and Pinckard R.N. Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues. Lab. Invest. 46 (1982) 422-427
116. Pirotzky E., Page C.P., Roubin R., Pfister A., Paul W., Bonnet J., and Benveniste J. PAF-acether- induced plasma exudation in rat skin is independent of platelets and neutrophils. Microcirc. Endothel. Lymphat. 1 (1984) 107-122
117. Hwang S.B., Li C.L., Lam M.H., and Shen T.Y. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by platelet-activating factor antagonists. Lab. Invest. 52 (1985) 617-630
118. Grandel K.E., Wardlow L.W., and Farr R.S. Platelet-activating factor in sputum of patients with asthma and COPD. Fed. Proc. 44 (1985) 184
119. Stenton S.C., Court E.N., Kingston W.P., Goadby P., Kelly C.A., Duddridge M., Ward C., Hendrick D.J., and Walters E.H. Platelet-activating factor in bronchoalveolar lavage fluid from asthmatic subjects. Eur. Respir. J. 3 (1990) 408-413
120. Kurosawa M., Yamashita T., and Kurimoto F. Increased levels of blood platelet-activating factor in bronchial asthmatic patients with active symptoms. Allergy 49 (1994) 60-63
121. Tsukioka K., Matsuzaki M., Nakamura M., Kayahara H., and Nakagawa T. Increased plasma level of platelet-activating factor (PAF) and decreased serum PAF-acetylhydrolase (PAFAH) activity in adults with bronchial asthma. J. Investig. Allergol. Clin Immunol. 6 (1996) 22-29
122. Hsieh K.H., and Ng C.K. Increased plasma platelet-activating factor in children with acute asthmatic attacks and decreased in vivo and in vitro production of platelet-activating factor after immunotherapy. J. Allergy Clin. Immunol. 91 (1993) 650-657
123. Chan-Yeung M., Lam S., Chan H., Tse K.S., and Salari H. The release of platelet-activating factor into plasma during allergen-induced bronchoconstriction. J. Allergy Clin Immunol. 87 (1991) 667-673
124. Shirasaki H., Nishikawa M., Adcock I.M., Mak J.C., Sakamoto T., Shimizu T., and Barnes P.J. Expression of platelet-activating factor receptor mRNA in human and guinea pig lung. Am. J. Respir. Cell Moll. Biol. 10 (1994) 533-537
125. Stafforini D.M., Numao T., Tsodikov A., Vaitkus D., Fukuda T., Watanabe N., Fueki N., McIntyre T.M., Zimmerman G.A., Makino S., and Prescott S.M. Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. J. Clin. Invest. 103 (1999) 989-997
126. Ito S., Noguchi E., Shibasaki M., Yamakawa-Kobayashi K., Watanabe H., and Arinami T. Evidence for an association between plasma platelet-activating factor acetylhydrolase deficiency and increased risk of childhood atopic asthma. J. Hum. Genet. 47 (2002) 99-101
127. Yokouchi Y., Nukaga Y., Shibasaki M., Noguchi E., Kimura K., Ito S., Nishihara M., Yamakawa-Kobayasi K., Takeda K., Imoto N., Ichikawa K., Matsui A., Hamaguchi H., and Arinami T. Significant evidence for linkage of mite-sensitive childhood asthma to chromosome 5q31-q33 near the interleukin 12 B locus by a genome-wide search in Japanese families. Genomics 66 (2000) 152-160
128. Satoh N., Asano K., Naoki K., Fukunaga K., Iwata M., Kanazawa M., and Yamaguchi K. Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma. Am. J. Respir. Crit. Care Med. 159 (1999) 974-979
129. Naoki K., Asano K., Satoh N., Fukunaga K., Oguma T., Shiomi T., Suzuki Y., Nakajima T., Niimi K., Shiraishi Y., Ishizaka A., and Yamaguchi K. PAF responsiveness in Japanese subjects with plasma PAF acetylhydrolase deficiency. Biochem. Biophys. Res. Commun. 317 (2004) 205-210
130. Kruse S., Mao X.Q., Heinzmann A., Blattmann S., Roberts M.H., Braun S., Gao P.S., Forster J., Kuehr J., Hopkin J.M., Shirakawa T., and Deichmann K.A. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am. J. Hum. Genet. 66 (2000) 1522-1530
131. Henderson Jr. W.R., Lu J., Poole K.M., Dietsch G.N., and Chi E.Y. Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model. J. Immunol. 164 (2000) 3360-3367
132. Henig N.R., Aitken M.L., Liu M.C., Yu A.S., and Henderson Jr. W.R. Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses. Am. J. Respir. Crit. Care Med. 162 (2000) 523-527
133. Imaizumi T., Stafforini D.M., Yamada Y., McIntyre T.M., Prescott S.M., and Zimmerman G.A. Platelet-activating factor: a mediator for clinicians. J. Intern. Med. 238 (1995) 5-20
134. Pinckard R.N., Farr R.S., and Hanahan D.J. Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils. J. Immunol. 123 (1979) 1847-1857
135. Nagaoka J., Harada K., Kimura A., Kobayashi S., Murakami M., Yoshimura T., Yamada K., Asano O., Katayama K., and Yamatsu I. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4-octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models. Arzneimittelforschung 41 (1991) 719-724
136. Terashita Z., Kawamura M., Takatani M., Tsushima S., Imura Y., and Nishikawa K. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. J. Pharmacol. Exp. Ther. 260 (1992) 748-755
137. Thompson W.A., Coyle S., Van Zee K., Oldenburg H., Trousdale R., Rogy M., Felsen D., Moldawer L., and Lowry S.F. The metabolic effects of platelet-activating factor antagonism in endotoxemic man. Arch. Surg. 129 (1994) 72-79
138. Matsumoto K., Taki F., Kondoh Y., Taniguchi H., and Takagi K. Platelet-activating factor in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Clin. Exp. Pharmcol. Physiol. 19 (1992) 509-515
139. 2 in patients with septic shock and trauma. Int. Care Med. 20 (1994) 555-561
140. Svetlov S.I., Howard K.M., Miwa M., Flickinger B.D., and Olson M.S. Interaction of platelet-activating factor with rat hepatocytes: uptake, translocation, metabolism, and effects on PAF-acetylhydrolase secretion and protein tyrosine phosphorylation. Arch. Biochem. Biophys. 327 (1996) 113-122
141. Ishii S., Nagase T., Tashiro F., Ikuta K., Sato S., Waga I., Kume K., Miyazaki J., and Shimizu T. Bronchial hyper-reactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. EMBO J. 16 (1997) 133-142
142. Ishii S., Kuwaki T., Nagase T., Maki K., Tashiro F., Sunaga S., Cao W.H., Kume K., Fukuchi Y., Ikuta K., Miyazaki J., Kumada M., and Shimizu T. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J. Exp. Med. 187 (1998) 1779-1788
143. Xu X.H., Shah P.K., Faure E., Equils O., Thomas L., Fishbein M.C., Luthringer D., Xu X.P., Rajavashisth T.B., Yano J., Kaul S., and Arditi M. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 104 (2001) 3103-3108
144. Fan J., Kapus A., Marsden P.A., Li Y.H., Oreopoulos G., Marshall J.C., Frantz S., Kelly R.A., Medzhtov R., and Rotstein O.D. Regulation of Toll-like receptor 4 expression in the lung following hemorrhagic shock and lipopolysaccharide. J. Immunol. 168 (2002) 5252-5259
145. Cao Y., Stafforini D.M., Zimmerman G.A., McIntyre T.M., and Prescott S.M. Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation. J. Biol. Chem. 13 (1998) 4012-4020
146. Patrick D.A., Moore E.E., Moore F.A., Biffl W.L., and Barnett C.C. Reduced PAF-acetylhydrolase activity is associated with postinjury multiple organ failure. Shock 7 (1997) 170-174
147. Poeze M., Froon A.H., Ramsay G., Buurman W.A., and Greve J.W. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective multicenter, double-blind, randomized phase II trial. Shock 14 (2000) 421-428
148. Vincent J., Spapen H., Bakker J., Webster N.R., and Curtis L. Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit. Care Med. 28 (2000) 638-642
149. Fukuda Y., Kawashima H., Saito K., Inomata N., Matsui M., and Nakanishi T. Effect of human plasma-type platelet-activating factor acetylhydrolase in two anaphylactic shock models. Eur. J. Pharmacol. 390 (2000) 203-207
150. Schuster D.P., Metzler M., Opal S., Lowry S., Balk R., Abraham E., Levy H., Slotman G., Coyne E., Souza S., and Pribble J. Pafase ARDS Prevention Study Group. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: phase IIb, multicenter, randomized placebo-controlled, clinical trial. Crit. Care Med. 31 (2003) 1861-1862
151. Opal S., Laterre P.F., Abraham E., Francois B., Wittebole X., Lowry S., Dhainaut J.F., Warren B., Dugernier T., Lopez A., Sanchez M., Demeyer I., Jauregui L., Lorente J.A., McGee W., Reinhart K., Kljucar S., Souza S., and Pribble J. the Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit. Care Med. 32 (2004) 332-341
152. Claus R.A., Russwurm S., Dohrn B., Bauer M., and Losche W. Plasma platelet-activating factor acetylhydrolase activity in critically ill patients. Crit. Care Med. 33 (2005) 1416-1419
153. Serban M., Tanaseanu C., Kosaka T., Vidulescu C., Stoian I., Marta D.S., Tanaseanu S., and Moldoveanu E. Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus. J. Cell Mol. Med. 6 (2002) 643-647
154. Winkler K., Abletshauser C., Hoffmann M.M., Friedrich I., Baumstark M.W., Wieland H., and Marz W. Effect of fluvastatin slow-release on low-density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J. Clin. Endocrinol. Metab. 87 (2002) 5485-5490
155. Yamamoto I., Fujitsu J., Nohnen S., Igarashi T., Motomura T., Inaba M., Tsubakimori S., and Azuma J. Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients. Diabetes Res. Clin. Pract. 59 (2003) 219-224
156. Nakos G., Kitsiouli E., Tsangaris I., and Lekka M.E. Bronchoalveolar lavage fluid characteristics of early intermediate and late phases of ARDS: alterations in leukocytes, proteins, PAF and surfactant components. Int. Care Med. 24 (1998) 296-303
157. Nakos G., Pneuimatikos J., Tsangaris I., Tellis C., and Lekka M. Protein and phospholipids in BAL from patients with hydrostatic pulmonary edema. Am. J. Respir. Crit. Care Med. 155 (1997) 945-951
158. Grissom C.K., Orme Jr. J.F., Richer L.D., McIntyre T.M., Zimmerman G.A., and Elstad M.R. Platelet-activating factor acetylhydrolase is increased in lung lavage fluid from patients with acute respiratory distress syndrome. Crit. Care Med. 31 (2003) 770-775
159. Triggiani M., De Marino V., Sofia M., Faraone S., Ambrosio G., Carratu L., and Marone G. Characterization of platelet-activating factor acetylhydrolase in human bronchoalveolar lavage. Am. J. Respir. Crit. Care Med. 156 (1997) 94-100
160. Milionis H.J., Tambaki A.P., Kanioglou C.N., Elisaf M.S., Tselepis A.D., and Tsatsoulis A. Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor acetylhydrolase in patients with subclinical hypothyroidism: a potential anti-atherogenic effect. Thyroid 15 (2005) 455-460
161. Rizos E., Tambaki A.P., Gazi I., Tselepis A.D., and Elisaf M. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins, Leukot. Essent. Fat. Acids 72 (2005) 203-209
162. Liberopoulos E.N., Papavasiliou E., Miltiadous G.A., Cariolou M., Siamopoulos K.C., Tselepis A.D., and Elisaf M.S. Alteration of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Perit. Dial. Int. 24 (2004) 580-589
163. Cederholm A., Svenungsson E., Stengel D., Fei G.Z., Pockley A.G., Ninio E., and Frostegard J. Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum. 50 (2004) 2869-2876